Investors Purchase High Volume of Insmed Call Options (NASDAQ:INSM)

Insmed Incorporated (NASDAQ:INSMGet Free Report) was the target of unusually large options trading activity on Thursday. Stock traders bought 10,561 call options on the stock. This represents an increase of approximately 215% compared to the typical volume of 3,356 call options.

Wall Street Analyst Weigh In

A number of research analysts recently commented on INSM shares. JPMorgan Chase & Co. raised their price objective on shares of Insmed from $36.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, May 29th. StockNews.com upgraded Insmed from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Stifel Nicolaus upped their price objective on Insmed from $39.00 to $67.00 and gave the company a “buy” rating in a report on Friday, May 31st. TD Cowen raised their target price on Insmed from $45.00 to $67.00 and gave the company a “buy” rating in a research note on Wednesday, May 29th. Finally, UBS Group boosted their price target on shares of Insmed from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, May 29th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $59.25.

View Our Latest Analysis on INSM

Insider Transactions at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 21,195 shares of the company’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $55.00, for a total value of $1,165,725.00. Following the completion of the transaction, the insider now owns 106,134 shares in the company, valued at approximately $5,837,370. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider John Drayton Wise sold 5,088 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $25.47, for a total value of $129,591.36. Following the completion of the sale, the insider now owns 123,259 shares of the company’s stock, valued at $3,139,406.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Martina M.D. Flammer sold 21,195 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $55.00, for a total transaction of $1,165,725.00. Following the transaction, the insider now directly owns 106,134 shares in the company, valued at approximately $5,837,370. The disclosure for this sale can be found here. Over the last quarter, insiders sold 295,842 shares of company stock worth $13,762,062. Insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Insmed

Institutional investors have recently bought and sold shares of the business. Rafferty Asset Management LLC increased its stake in shares of Insmed by 17.4% in the fourth quarter. Rafferty Asset Management LLC now owns 321,087 shares of the biopharmaceutical company’s stock worth $9,950,000 after acquiring an additional 47,563 shares during the last quarter. Norges Bank acquired a new position in Insmed in the 4th quarter worth about $45,029,000. Artia Global Partners LP purchased a new stake in shares of Insmed during the 4th quarter worth about $2,322,000. Walleye Capital LLC acquired a new stake in shares of Insmed during the 3rd quarter valued at about $1,820,000. Finally, Jennison Associates LLC bought a new stake in shares of Insmed in the 4th quarter valued at approximately $3,745,000.

Insmed Stock Up 0.2 %

Shares of INSM stock traded up $0.13 during trading hours on Thursday, reaching $61.78. 2,591,329 shares of the stock traded hands, compared to its average volume of 2,470,030. The business has a fifty day moving average price of $33.10 and a 200 day moving average price of $29.81. Insmed has a 1-year low of $18.77 and a 1-year high of $64.98. The firm has a market capitalization of $9.18 billion, a PE ratio of -11.96 and a beta of 1.12.

Insmed (NASDAQ:INSMGet Free Report) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.16. The firm had revenue of $75.50 million for the quarter, compared to analyst estimates of $77.76 million. Insmed’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same period last year, the firm earned ($1.17) earnings per share. Research analysts expect that Insmed will post -4.51 earnings per share for the current fiscal year.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Featured Stories

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.